Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

Diabetic Medicine : a Journal of the British Diabetic Association
C SeifarthM A Nauck

Abstract

GLP-1, an incretin hormone of the enteroinsular axis with insulinotropic and glucagonostatic activity, is secreted after nutrient ingestion. GLP-1 is mainly produced by intestinal L-cells in the lower gastrointestinal tract (GIT); simple carbohydrates are absorbed in the upper GIT and alpha-glucosidase inhibition leads to augmented and prolonged GLP-1 release in normal subjects. In a cross-over study, 100 mg acarbose or placebo was administered simultaneously with 100 g sucrose to 11 hyperglycaemic Type 2 diabetic patients poorly controlled with diet and sulphonylureas. Plasma levels of GLP-1, insulin, C-peptide, glugacon, GIP, glucose and H2-exhalation were measured over 6 h. Differences in the integrated responses over the observation period were evaluated by repeated measurement analysis of variance with fasting values used as covariates. With acarbose, sucrose reached the colon 60-90 min after ingestion as indicated by a significant increment in breath hydrogen exhalation (p = 0.005). After an early GLP-1 increment 15 min after sucrose under both conditions, GLP-1 release was prolonged in the acarbose group (p = 0.001; significant from 210 to 360 min.). Initially (0-150 min), glucose (p = 0.001), insulin (p = 0.001), and GI...Continue Reading

Citations

Apr 23, 2011·Journal of Nutritional Science and Vitaminology·Tohru HiraHiroshi Hara
Nov 9, 2007·Annual Review of Physiology·Darleen SandovalRandy J Seeley
Jul 5, 2005·Expert Opinion on Investigational Drugs·J J Holst
Oct 13, 2005·Diabetes, Obesity & Metabolism·Daniel E RosenbergBarry J Goldstein
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·R E Wachters-HagedoornR J Vonk
May 11, 2007·Diabetes, Obesity & Metabolism·D MaggsM A Nauck
Sep 28, 2014·Expert Opinion on Pharmacotherapy·Eva W IepsenJens J Holst
Nov 8, 2005·The American Journal of Medicine·Diana GentilcoreKaren L Jones
Jan 14, 2004·Canadian Journal of Physiology and Pharmacology·Patricia L Brubaker, Younes Anini
Mar 29, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·M HorowitzM Samsom
Jun 20, 2002·Pharmazie in unserer Zeit·Holger Neye
Jun 10, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hiroaki UenoMasamitsu Nakazato
Sep 22, 2007·Diabetes/metabolism Research and Reviews·Stefano Del PratoPiero Marchetti
Jan 5, 2008·Current Diabetes Reports·Ariane Godbout, Jean-Louis Chiasson
Mar 1, 2008·Cardiovascular Drugs and Therapy·Markolf HanefeldCarsta Koehler
Apr 26, 2008·Diabetes, Obesity & Metabolism·Kasper AaboeJens Juul Holst
Oct 25, 2008·Drugs & Aging·Angela M AbbatecolaGiuseppe Paolisso
Mar 11, 2006·Drugs·Guillaume CharpentierMichel Varroud-Vial
Nov 20, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sandi-Jo Galati, Elliot J Rayfield
Apr 20, 2014·Current Diabetes Reports·Kristine FærchMarit Eika Jørgensen
Sep 1, 2014·Expert Review of Endocrinology & Metabolism·Sanjay Kalra
Mar 20, 2020·Journal of Food Biochemistry·Rocio Campos-VegaMaría Dolores Del Castillo Bilbao
Jan 8, 2016·Hormone Molecular Biology and Clinical Investigation·Mark F McCarty
Oct 9, 2007·The American Journal of Clinical Nutrition·Rania Abou Samra, G Harvey Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.